Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of ...

A US appeals court has ruled that Regeneron and Sanofi’s Praluent can stay on the market while they appeal a patent case from rival Amgen that blocked them from selling it. Last month ...

Praluent, a PCSK9 inhibitor, was developed by Regeneron (REGN) and Sanofi (SNY) under a global collaboration agreement. The medication is currently indicated to treat both children and adults with ...

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don’t have many side effects, it is very expensive.

Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales ...